HEARTCARE-B (06609): Registration Application for Self-Expanding Intracranial Drug-Eluting Stent Accepted by NMPA
Stock News
Jan 20
HEARTCARE-B (06609) announced that the registration application for its self-expanding intracranial drug-eluting stent, developed by the Group, has been accepted by China's National Medical Products Administration (NMPA). This self-expanding intracranial drug-eluting stent is intended for the treatment of intracranial atherosclerotic stenosis, providing support and opening for narrowed and obstructed lumens, while effectively preventing in-stent restenosis. According to publicly available information, there are currently no similar products approved for market launch globally, and the company's research and development progress for this type of product is at a leading level within the industry.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.